Loading...

Increased engagement

On average, FreeStyle Libre 14 day system users tested more often than the 6-10 glucose tests per day recommended by the ADA.3,4,* More frequent glucose monitoring with the FreeStyle Libre 14 day system is associated with better outcomes.⁵

>2x

more patients reported knowing what to do after measuring glucose compared to when they used blood glucose meters

95%

reported having a better understanding of their glucose fluctuationsƗ

62%

reported that family and roommates were less worried about their diabetes when using the FreeStyle Libre 14 day systemƗ

Real-time glucose readings with a painless8 scan

List Icon Image

Small, discreet, and easy for patients8

List Icon Image

Clinically proven to be accurate,9 stable, and consistent over 14 days without the need for fingerstick calibration

List Icon Image

Continuously measures glucose every minute and stores readings every 15 minutes

FreeStyle Libre 14 day CGM system available for prescription with sensor, reader, and smartphone app as the best CGM technology in the U.S.

Improved patient adherence and engagement§,|| through FreeStyle Libre digital health tools

Digital health tools (LibreView, FreeStyle LibreLink app,#,**,†† and LibreLinkUpǂǂ) that work together for seamless diabetes management.

Fill their sensors more§

Are more adherent to sensor use§

Continue using sensors after 12 months (87%)||

Phone and CGM FreeStyle Libre sensor and reader product image

Contact us

* 2020 ADA recommendation for patients self-monitoring blood glucose (SMBG) on multiple-dose insulin or insulin pump therapy.
Ɨ Compared to patients using SMBG.
ǂ Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
§ In comparison to FreeStyle 14 day reader users.7
|| In comparison to FreeStyle LibreLink app patients not sharing with their physicians.7
¶ LibreView is developed, distributed, and supported by Newyu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
# The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app.
** Use of the FreeStyle LibreLink app requires registration with LibreView, a service provided by Abbott and Newyu, Inc.
ƗƗ Medicare coverage is available for FreeStyle Libre 14 day systems for cell phone use if FreeStyle LibreLink is used in conjunction with the FreeStyle Libre and FreeStyle Libre 14 day readers. Patients must meet Medicare eligibility coverage criteria. Local Coverage Article: Glucose Monitor Policy Article (A52464), May 2017.
ǂǂ The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView, a service provided by Abbott and Newyu, Inc.
§§ Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.


References: 1. Dunn T, et al. Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage. Diabetes Technol Ther. 2017;19(suppl 1). doi:10.1089/dia.2017.2525.abstracts 2. Jangam S, et al. Sustained improvement in glycaemic control following flash glucose monitoring: a worldwide observational analysis. Diabetes Technol Ther. 2018;20(suppl 1):A-25. doi:10.1089/dia.2018.2525.abstracts 3. American Diabetes Association. Diabetes Care. 2020;43(suppl 1):S77-S88. 4. Lang J, et al. Diabetes. 2019;68(suppl 1):972-P. doi:10.2337/db19-972-P 5. Dunn TC, et al. [published online December 24, 2017]. Diabetes Res Clin Pract. 2018;137:37-46. 6. Fokkert M, et al. BMJ Open Diabetes Res Care. 2019;7(1):e000809. doi:10.1136/bmjdrc-2019-000809 7. Data on file. Abbott Diabetes Care. 8. Haak T, et al. Diabetes Ther. 2017;8(1):55-73. 9. FreeStyle Libre 14 day User's Manual.

ADC-17129 v2.0 07/20

Indications and Important Safety Information

FreeStyle Libre 14 day system: The FreeStyle Libre 14 day Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions. The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre 14 day system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre 14 day system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information. For full indications for use and safety information, see more here.

FreeStyle Libre 2 system: The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.*

WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit * www.freestylelibre.us for detailed indications for use and safety information.

* Please refer to www.freestylelibre.us for the indications and important safety information.

The shape of the circle sensor unit, FreeStyle, Libre, and related brand marks are owned by Abbott. Other trademarks are the property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company. Product images are for illustrative purposes only.

ADC-25347 v2.0 09/20